
Clozapine
Clozapine is the reference treatment for schizophrenia that has not responded to other antipsychotics. In a landmark 6-week trial, 30% of treatment-resistant patients responded to clozapine versus 4% on chlorpromazine, a meta-analysis of 25 comparisons found it superior to other antipsychotics for treatment-resistant illness, and a 2-year trial found less suicidal behavior than with olanzapine. It needs regular blood counts and careful dose titration. Smoking, caffeine and St. John's wort are the high-severity interactions: changes in smoking or caffeine can move clozapine levels, and St. John's wort can lower them.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Adults with schizophrenia who have not responded adequately to standard antipsychotics, and adults with schizophrenia or schizoaffective disorder at chronic risk of suicidal behavior, under a prescriber who arranges blood count monitoring
Common dosing range
Set by your prescriber. The Clozaril label starts at 12.5 mg once or twice daily, increases slowly to a target of 150 mg to 225 mg twice daily by the end of 2 weeks, then by up to 100 mg once or twice weekly if needed, to a maximum of 450 mg twice daily (900 mg a day)
When to expect effects
The pivotal treatment-resistance trial measured response at 6 weeks; the suicidal-behavior trial ran 2 years
Watch out for
Boxed warning for severe neutropenia, orthostatic hypotension with slow heart rate and fainting, seizures, myocarditis and cardiomyopathy, and higher death rates in older adults with dementia-related psychosis. Needs regular blood counts. Tell your prescriber before any change in smoking or caffeine intake. Severe constipation can be dangerous; report it early
What is it
Clozapine is a prescription atypical antipsychotic, sold as generic tablets and orally disintegrating tablets, as Clozaril tablets (25 mg and 100 mg) and as Versacloz oral suspension (50 mg per mL). The Clozaril label approves it for two uses: severely ill people with schizophrenia who have not responded well enough to standard antipsychotic treatment, and reducing the risk of recurrent suicidal behavior in people with schizophrenia or schizoaffective disorder who are at chronic risk. For treatment-resistant schizophrenia, the label says that because of the risks of severe neutropenia (a dangerous drop in a type of white blood cell) and seizures, it should be used only in people who have not responded well enough to standard antipsychotic treatment. Regular blood counts are part of treatment. Its boxed warning also covers low blood pressure on standing, slow heart rate and fainting, inflammation of the heart muscle, and higher death rates in older adults with dementia-related psychosis. For supplements and drinks, the two interactions this page rates are smoking (high) and caffeine (high): both change how fast the liver clears clozapine.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
treatment-resistant schizophrenia Good Evidence | Large; 30% versus 4% responders | Adults with schizophrenia who have not responded to at least three antipsychotics | Measured at 6 weeks |
treatment-resistant schizophrenia (meta-analysis) Good Evidence | Moderate; number needed to treat of 9 | Adults with treatment-refractory schizophrenia, especially those with higher baseline psychosis scores | Short-term and long-term trials; reassess if no response by 6 months |
suicidal behavior in schizophrenia or schizoaffective disorder Good Evidence | Moderate; 24% lower hazard of suicidal behavior than olanzapine | Adults with schizophrenia or schizoaffective disorder with previous suicide attempts or current suicidal thinking | Measured over 2 years |
treatment-resistant schizophrenia
- Effect
- Large; 30% versus 4% responders
- Best fit
- Adults with schizophrenia who have not responded to at least three antipsychotics
- Time
- Measured at 6 weeks
treatment-resistant schizophrenia (meta-analysis)
- Effect
- Moderate; number needed to treat of 9
- Best fit
- Adults with treatment-refractory schizophrenia, especially those with higher baseline psychosis scores
- Time
- Short-term and long-term trials; reassess if no response by 6 months
suicidal behavior in schizophrenia or schizoaffective disorder
- Effect
- Moderate; 24% lower hazard of suicidal behavior than olanzapine
- Best fit
- Adults with schizophrenia or schizoaffective disorder with previous suicide attempts or current suicidal thinking
- Time
- Measured over 2 years
Evidence for 3 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
treatment-resistant schizophrenia
Disease adjunctIn a multicenter, double-blind trial, adults with schizophrenia who had failed at least three different antipsychotics first received haloperidol for six weeks. The 268 who still did not improve were randomized to clozapine (up to 900 mg a day) or chlorpromazine (up to 1800 mg a day) for six weeks. Using criteria set in advance, 30% of clozapine patients responded versus 4% on chlorpromazine, and clozapine improved both positive and negative symptoms more. The trial was short, and no cases of agranulocytosis occurred during it.
Bottom line: In people who had failed several antipsychotics, clozapine produced far more responders than chlorpromazine over 6 weeks.
treatment-resistant schizophrenia (meta-analysis)
Disease adjunctA 2016 systematic review and meta-analysis pooled 21 papers with 25 comparisons of clozapine against first- and second-generation antipsychotics in treatment-refractory schizophrenia. The number needed to treat was 9. Clozapine was better for positive symptoms in both the short and long term, and in the short term only it was better for total and negative symptoms, with higher response rates. Funding source and dose affected the results. The authors suggest that if there is no response by 6 months, medicines with fewer side effects should be considered.
Bottom line: Across 25 comparisons, clozapine outperformed other antipsychotics for treatment-refractory schizophrenia, with about 1 extra responder per 9 people treated.
suicidal behavior in schizophrenia or schizoaffective disorder
Disease adjunctThe International Suicide Prevention Trial (InterSePT) randomized 980 people with schizophrenia or schizoaffective disorder at high risk of suicide to clozapine or olanzapine for 2 years; 26.8% were treatment-resistant. Suicidal behavior was less common with clozapine (hazard ratio 0.76, 95% CI 0.58 to 0.97). Fewer clozapine patients attempted suicide (34 vs 55) or needed hospital stays to prevent suicide (82 vs 107). Deaths by suicide were few and did not differ (5 vs 3). The trial was open-label, with masked raters for the main endpoints.
Bottom line: Over 2 years, clozapine reduced suicide attempts and suicide-prevention hospital stays compared with olanzapine; deaths by suicide were few and did not differ between the drugs.
How it works
How to take it
What to track
Bottom line: Your prescriber sets and adjusts the dose and arranges the blood tests; never restart at your old dose after missed days, and tell your prescriber before you change smoking or caffeine habits.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Severe neutropenia (boxed warning): a dangerous drop in neutrophils that raises the risk of serious and fatal infections. The risk appears greatest in the first 18 weeks. A baseline ANC is required before starting, with regular ANC monitoring throughout treatment.
Orthostatic hypotension, bradycardia, syncope and cardiac arrest (boxed warning): highest during the first dose increases, possible at doses as low as 12.5 mg, and when restarting after even a brief break. This is why the dose starts low and rises slowly.
Seizures (boxed warning): dose-related, with an estimated cumulative incidence of about 5% at one year in premarketing testing. The label cautions against activities where sudden loss of consciousness could be dangerous, such as driving, swimming or climbing.
Myocarditis, pericarditis, cardiomyopathy and mitral valve incompetence (boxed warning): can be fatal. Myocarditis most often appears in the first 2 months. Chest pain, fast heartbeat, palpitations, shortness of breath, fever or flu-like symptoms need prompt medical review.
Increased mortality in elderly patients with dementia-related psychosis (boxed warning): in placebo-controlled trials of antipsychotics, deaths were about 4.5% versus 2.6% on placebo over about 10 weeks. Clozapine is not approved for this use.
Severe gastrointestinal hypomotility: from constipation to paralytic ileus, bowel obstruction, perforation and death. The risk rises with other anticholinergic medicines, and the label calls for frequent checks of bowel function.
Other label warnings: QT prolongation and life-threatening arrhythmias, high blood sugar and diabetes, high cholesterol and triglycerides, weight gain, neuroleptic malignant syndrome, liver injury, eosinophilia, blood clots in the lungs, falls, tardive dyskinesia, and return of psychosis with cholinergic rebound (sweating, headache, nausea, vomiting, diarrhea) after abrupt stopping.
Who should avoid it
- People with a history of hypersensitivity to clozapine (for example photosensitivity, vasculitis, erythema multiforme or Stevens-Johnson syndrome) or to any ingredient (contraindicated)
- People whose baseline ANC is below 1500/μL (below 1000/μL with benign ethnic neutropenia): the label does not recommend starting
- Older adults with dementia-related psychosis: not approved, with a higher risk of death
- Children and teens: the label says safety and effectiveness in pediatric patients have not been established
Pregnancy & breastfeeding
Pregnancy: the Clozaril label says published studies over decades of use have not established a drug-associated risk of major birth defects, miscarriage or other harmful outcomes. Babies exposed to antipsychotics, including clozapine, in the third trimester are at risk of movement (extrapyramidal) and withdrawal symptoms after delivery, such as agitation, abnormal muscle tone, tremor, sleepiness, breathing trouble and feeding problems; some needed prolonged hospital care. Untreated schizophrenia also carries risks, including relapse and preterm birth. A national pregnancy registry for atypical antipsychotics collects outcomes. Breastfeeding: clozapine passes into breast milk. There is one case report of sedation and a report of agranulocytosis in infants exposed through breast milk. The label says to weigh the benefits of breastfeeding against the mother's need for clozapine, and that exposed infants should be watched for excess sleepiness and checked for neutropenia.
Interactions
Tobacco smoke speeds up CYP1A2, the main enzyme that clears clozapine; the label calls it a moderate CYP1A2 inducer and says to consider a lower clozapine dose when it stops. A meta-analysis of 4 studies (196 patients) found clozapine levels per dose clearly lower in smokers and estimated non-smokers need about half the dose for the same level, and in 12 heavy smokers who quit, enzyme activity fell within days (half-life about 39 hours). Tell your prescriber before quitting, cutting down or entering a smoke-free hospital, so your dose and levels can be reviewed.
The label lists caffeine as a CYP1A2 inhibitor that can raise clozapine levels and says to monitor closely and consider a lower dose. In 12 healthy non-smoking men given a single 12.5 mg dose of clozapine, 400 to 1000 mg of caffeine a day (average 550 mg) raised clozapine exposure by 19%, and a published case describes life-threatening clozapine toxicity in a man stable for 5 years who started drinking about four energy drinks (about 600 mg of caffeine) a day. Keep your caffeine intake steady, and talk to your prescriber before a big change, such as starting energy drinks or quitting coffee.
These can raise clozapine levels; in one study fluvoxamine raised them about three-fold. The label reduces the clozapine dose to one third when they are used together and returns to the original dose when they stop. Make sure every prescriber knows you take clozapine before a new antibiotic or antidepressant.
These lower clozapine levels and can make it less effective; the label says using them together is not recommended. When an inducer is stopped, clozapine levels can rise, so the label says to consider a lower clozapine dose then. Review any change with your prescriber.
Clozapine already has strong anticholinergic effects. The label says adding other anticholinergic drugs raises the risk of anticholinergic toxicity and of severe bowel slowing, and to avoid the combination when possible. This includes some over-the-counter sleep aids and allergy medicines with diphenhydramine; ask your pharmacist before using them.
The label names St. John's wort as a strong CYP3A4 inducer, which can lower clozapine levels and make it less effective, and says using clozapine with strong CYP3A4 inducers is not recommended. One published case describes a stable patient whose clozapine level fell and whose condition worsened after she began taking St. John's wort, with both returning to normal after the herb was stopped. If you already take both, do not stop the herb on your own: clozapine levels can rise when an inducer is stopped, so talk to your prescriber first.
Documented interactions
Evidence-graded pair pages with sources, dosing notes, and timing guidance, a complement to the narrative section above.
Warnings (3)
+ caffeine
highCaffeine and clozapine are both broken down by the liver enzyme CYP1A2, and caffeine competitively inhibits it. Large changes in caffeine intake - especially starting or stacking energy drinks - can raise clozapine to toxic levels, with a documented case report of severe toxicity and multiorgan failure.
+ st. john's wort
highSt. John's wort speeds up CYP3A4, one of the liver enzymes that clear clozapine, and the clozapine label names it as a strong CYP3A4 inducer. Inducers can lower clozapine blood levels and make it less effective, and the label says using clozapine with strong CYP3A4 inducers is not recommended. One published case describes a woman with schizophrenia, stable on clozapine, whose clozapine level fell and whose condition worsened after she began taking St. John's wort on her own; both returned to normal after she stopped the herb.
+ smoking
highPolycyclic aromatic hydrocarbons in tobacco smoke (not nicotine) induce CYP1A2, the liver enzyme that handles most clozapine metabolism; the Clozaril label calls tobacco smoke a moderate CYP1A2 inducer. Smokers tend to have lower clozapine levels: a meta-analysis of 4 studies (196 patients) estimated that non-smokers need about half the dose of smokers for the same level. The greater danger is stopping smoking: in 12 heavy smokers who quit, enzyme activity fell with a half-life of about 39 hours, so clozapine levels can climb within days, risking sedation, seizures and toxicity unless the dose is reviewed.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Does smoking affect clozapine?⌄
Yes. Tobacco smoke speeds up the liver enzyme that clears clozapine, so smokers usually need a higher dose. When you stop smoking, clozapine levels can rise within days and cause side effects. This page rates the pair high. Tell your prescriber before you quit, cut down, switch products or enter a smoke-free hospital, so the dose and levels can be checked.
Can I drink coffee or energy drinks while taking clozapine?⌄
Talk to your prescriber first. Caffeine slows the enzyme that clears clozapine, and a large increase, such as several energy drinks a day, has been linked to serious clozapine toxicity in a published case. This page rates the pair high. The safest approach the sources support is to keep your caffeine intake steady and to tell your prescriber before any big change.
Why do I need blood tests on clozapine?⌄
Clozapine can cause severe neutropenia, a drop in infection-fighting white blood cells. The label requires a baseline count and regular checks: weekly for the first 6 months, every 2 weeks for months 7 to 12, and monthly after that while counts stay normal. Report fever or a sore throat right away.
What should I do if I miss doses of clozapine?⌄
Contact your prescriber before taking more. The label says that after even one missed day, clozapine should be restarted at a lower dose, because restarting at the full dose can cause dizziness, fainting or a slow heart rate.
Is constipation on clozapine serious?⌄
It can be. The label warns that clozapine can slow the bowel enough to cause blockage, perforation and death, and that the risk rises with other anticholinergic medicines. Tell your care team early about fewer bowel movements, hard stools, belly pain or swelling, nausea or vomiting.
References by claim
treatment-resistant schizophrenia
Kane et al., 1988 · PubMed (1988) link
treatment-resistant schizophrenia (meta-analysis)
Siskind et al., 2016 · PubMed (2016) link
suicidal behavior in schizophrenia or schizoaffective disorder
Meltzer et al., 2003 · PubMed (2003) link
Safety
Clozaril (clozapine) tablets prescribing information · DailyMed (FDA label) link
Interaction: Smoking (tobacco cigarettes)
Interaction: Caffeine (coffee, tea, energy drinks, caffeine pills)
Interaction: St. John's wort (Hypericum perforatum)
Van Strater et al., 2012 · PubMed (2012) link
Track Clozapine with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
